CTOs on the Move

NeoGenomics

www.neogenomics.org

 
NeoGenomics Laboratories is a specialized genetics laboratory providing the latest diagnostic testing technologies to the pathology and oncology markets.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Marydawn Miller
Vice President of Information Technology Profile

Similar Companies

Amarillo Diagnostic Clinic

The pulmonary specialists at Amarillo Diagnostic Clinic specialize in treating patients with lung and respiratory disorders. Our Pulmonary Department has expanded into the diagnosis and treatment of sleep disorders. Our diagnostic facility includes

Pathology and Cytology Lab

Pathology and Cytology Lab is a Albany, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The U.S. Department of Energy's Thomas Jefferson National Accelerator Facility

Jefferson Lab is one of 17 Department of Energy national research laboratories and facilities.

Robertson Research Institute

Robertson Research Institute is a Saginaw, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DiaDexus

Diadexus is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. We pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating this biomarker`s utility. Our products are the only two FDA-cleared tests to measure Lp-PLA2: The PLAC® Test ELISA Kit first cleared by the FDA in 2003 and The PLAC® Test for Lp-PLA2 Activity cleared in December 2014. Our pipeline of advanced cardiac biomarkers includes biomarkers for heart failure, proADM, proET-1 and proANP. Each marker gives distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. Our portfolio of advanced cardiac biomarkers is available to be paired with novel therapeutics in development for indications where cardiovascular risk information would provide valuable insights. This information can be used by pharmaceutical companies in targeting the appropriate patient population and understanding the potential long-term side effects for their therapeutics, potentially avoiding long-term follow up studies.